Are liver enzyme rises significant with tigecycline use?

Tigecycline can cause elevations in liver enzymes, but the typical pattern and how often they’re clinically “significant” depends on what you mean by significant.

What’s commonly seen

In clinical use/trials, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) can rise. These elevations are often:

• Mild to moderate
• Asymptomatic (no jaundice)
• Occur during treatment
• Improve after stopping (in many patients)

How to judge “significant” elevations

Clinically significant liver effects are more concerning if you see:

• Marked transaminase increases (commonly thought of as ≥3× the upper limit of normal (ULN), and especially ≥5× ULN)
• Cholestatic pattern (e.g., ALP and bilirubin rise, particularly if bilirubin is elevated)
• Symptoms or signs of liver injury (fatigue, nausea, RUQ pain) or jaundice
• Hy’s law criteria (a specific marker of potential serious drug-induced liver injury): ALT/AST ≥3× ULN plus bilirubin >2× ULN without a clear alternative cause

Serious hepatotoxicity

Severe liver injury due to tigecycline is relatively uncommon, but it’s not impossible—so enzyme rises should still be monitored, especially in higher-risk patients.

Practical guidance

If you’re asking because of lab results, clinicians typically consider:

1. Degree of elevation (how many times ULN)
2. Bilirubin level (key for severity)
3. Trend (rising vs stable)
4. Other causes (sepsis, antibiotics co-administered, biliary obstruction, viral hepatitis, alcohol, ischemic hepatitis, etc.)

If you share specifics, I can help interpret

If you tell me:

• which enzymes (AST/ALT/ALP/GGT),
• the values (and ULN, if known),
• bilirubin,
• symptoms,
• and whether tigecycline is ongoing, I can give a more tailored sense of whether it looks “significant” and what thresholds are typically used.